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Abstract
Background: Depression is a prevalent and disabling mental disorder that frequently co-occurs with a wide range
of chronic conditions. Evidence has suggested that depression could be associated with excess all-cause mortality
across different settings and populations, although the causality of these associations remains unclear.
Methods: We conducted an umbrella review of systematic reviews and meta-analyses of observational studies. PubMed,
PsycINFO, and Embase electronic databases were searched through January 20, 2018. Systematic reviews and meta-
analyses that investigated associations of depression and all-cause and cause-specific mortality were selected for the
review. The evidence was graded as convincing, highly suggestive, suggestive, or weak based on quantitative criteria that
included an assessment of heterogeneity, 95% prediction intervals, small-study effects, and excess significance bias.
Results: A total of 26 references providing 2 systematic reviews and data for 17 meta-analytic estimates met inclusion
criteria (19 of them on all-cause mortality); data from 246 unique studies (N = 3,825,380) were synthesized. All 17
associations had P < 0.05 per random effects summary effects, but none of them met criteria for convincing evidence.
Associations of depression and all-cause mortality in patients after acute myocardial infarction, in individuals with heart
failure, in cancer patients as well as in samples from mixed settings met criteria for highly suggestive evidence. However,
none of the associations remained supported by highly suggestive evidence in sensitivity analyses that considered studies
employing structured diagnostic interviews. In addition, associations of depression and all-cause mortality in cancer and
post-acute myocardial infarction samples were supported only by suggestive evidence when studies that tried to adjust
for potential confounders were considered.
Conclusions: Even though associations between depression and mortality have nominally significant results in all assessed
settings and populations, the evidence becomes weaker when focusing on studies that used structured interviews and
those that tried to adjust for potential confounders. A causal effect of depression on all-cause and cause-specific mortality
remains unproven, and thus interventions targeting depression are not expected to result in lower mortality rates at least
based on current evidence from observational studies.
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Background
Major depressive disorder is a chronic and recurring con-
dition with an estimated lifetime prevalence of 14.6% and
11.1% in high- and lower- and middle-income countries,
respectively [1, 2]. In addition, major depressive disorder
is a leading source of disability worldwide [3, 4], and is as-
sociated with diminished quality of life and medical mor-
bidity [2, 4, 5]. An accumulating body of evidence also
indicates that major depressive disorder may confer a
higher risk for several non-communicable diseases (for ex-
ample, diabetes [6], obesity [7], stroke [8], acute myocar-
dial infarction [9], dementia [10], and physical health
multimorbidity [11]), while these chronic health condi-
tions appear to increase the likelihood of developing de-
pression [7, 12–15].
It has long been suggested that depression is associated
with elevated all-cause mortality [16, 17], and is an estab-
lished risk factor for completed suicide [18]. In addition, de-
pression has been associated with higher mortality rates
across several settings and populations, including commu-
nity samples, inpatients/outpatients, and patients with spe-
cific medical conditions (for example, stroke, diabetes, and
coronary heart disease) [9, 16, 19, 20]. However, consistent
evidence has not shown that specific interventions targeting
depression may increase survival in both community and
clinical samples. Furthermore, several confounding vari-
ables may account for the observed associations between
depression and survival, namely sociodemographic vari-
ables [21], physical inactivity [22, 23], higher smoking rates
[24], follow-up duration of studies [16], and co-occurring
medical and psychiatric conditions [5, 25].
Several individual systematic reviews and meta-analyses
have investigated the association between depression and
mortality across distinct populations (for example, in com-
munity samples as well as in samples with specific chronic
diseases) [16, 20, 26–28]. To synthesize and evaluate the
available evidence we conducted an umbrella review of
systematic reviews and meta-analyses that assessed the as-
sociation of depression and all-cause and cause-specific
mortality. The strength of the evidence supporting these
associations and hints of bias were evaluated using stan-
dardized approaches [8, 29–31].
Methods
Literature search
We conducted an umbrella review, which is the systematic
collection and assessment of multiple systematic reviews
and meta-analyses done in a specific research topic [29].
The PubMed/MEDLINE, EMBASE, and PsycINFO data-
bases were searched from inception up to January 20, 2018,
for systematic reviews and meta-analyses of observational
studies which examined the association of depression and
all-cause or cause-specific mortality. A pre-defined search
strategy was used (Additional file 1).
Eligibility criteria
We included systematic reviews and meta-analyses of ob-
servational epidemiological studies performed in humans
that assessed the impact of depression on all-cause or
cause-specific mortality in any specific population (for ex-
ample, community samples, samples with a specific medical
condition, inpatients, etc.). In addition, systematic reviews
and meta-analyses that solely investigated the association of
depression and suicide-related deaths were not considered;
this was not an aim of the current effort as depression is an
established risk factor for completed suicide [18]. However,
suicide-related deaths were considered in meta-analyses
that estimated the association of depression and all-cause
mortality across different populations. No language restric-
tions were considered for the selection of systematic re-
views and meta-analyses for this umbrella review. We
included unique observational studies derived from all
available systematic reviews and meta-analyses on a specific
topic. Whenever a meta-analysis included a lower number
of component studies compared to another meta-analysis
on the same topic, the former was excluded only if all its in-
dividual datasets were included in the larger meta-analysis.
Otherwise, we also extracted data from non-overlapping
datasets included only in the meta-analysis with fewer stud-
ies. This approach aimed to synthesize the largest evidence
possible derived from available systematic reviews and
meta-analyses. Across each eligible systematic review and/
or meta-analysis we considered studies in which the case
definition of depression was based on either International
Classification of Disease [32] (ICD), Diagnostic and Statis-
tical Manual of Mental Disorders [33] (DSM), or other
consensus-based acceptable criteria (e.g., the Research
Diagnostic Criteria [34]). We also included studies where
depression was assessed by means of a screening instru-
ment with a specific cutoff score (e.g., the Patient Health
Questionnaire-9 and the Beck Depression Inventory). We
excluded individual studies from eligible systematic reviews
and meta-analyses according to the following criteria: (1)
reported an association only for depressive symptoms (i.e.,
the association was reported for an increase in scores of a
depression rating scale instead of a possible diagnosis of de-
pression based on a screening tool with a cutoff point); (2)
considered other mental disorders (e.g., dysthymia) in the
mortality outcome assessment unless data for depression,
as defined above, was provided separately; (3) a diagnosis of
depression was based only on clinical evaluation without
any specification of the diagnostic criteria; (4) a diagnosis of
depression was based only on the use of antidepressants or
otherwise on a self-reported (or record-based) history of
depression; (5) the association was reported considering
other outcomes in addition to mortality (e.g., recurrence);
and (6) studies that provided results based on controls that
were not included in the original sample (for example, stud-
ies that estimated the associations of depression and
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mortality through standardized mortality ratios compared
with general population data external to the study sample).
Two authors (MOM and NV) independently screened
the titles and abstracts of retrieved references for eligi-
bility. The full-text articles of potentially eligible articles
were then independently scrutinized in detail by two in-
vestigators (MOM and NV). Disagreements were re-
solved through consensus or discussion with a third
investigator (CAK or AFC).
Data extraction
Data extraction was done independently by two investiga-
tors (MOM and NV) and, in case of discrepancies, a third
investigator made the final decision (CAK and AFC). For
each eligible reference, we recorded the first author, year,
journal of publication, specific populations evaluated and
the number of included studies. If a quantitative synthesis
was performed, we also extracted the most fully adjusted
study-specific risk estimates (relative risk, odds ratio, haz-
ard ratio, or incident risk ratio) and corresponding 95%
confidence intervals (CIs). When available, we also ex-
tracted the following variables from each study: number of
cases (number of death events in participants with depres-
sion), sample size, follow-up time, covariates included in
multivariable models, method used to define depression
(i.e., structured diagnostic interview or screening instru-
ment), study design (case-control, prospective cohort, or
retrospective cohort), specific population, as well as the
setting and country where the study was conducted.
Whenever studies used several control groups, we consid-
ered data from healthy controls as the control group. For
studies with no quantitative synthesis, the authors’ main
interpretations about their findings and reasons why a
meta-analysis was not conducted were recorded.
Statistical analysis and methodological quality appraisal
We based our analysis on the largest meta-analysis that
evaluated the association of depression and all-cause or
cause-specific mortality. Furthermore, all datasets from
similar meta-analyses that were not included in the lar-
gest available one were also considered (i.e., we included
all datasets from the smaller meta-analysis that did not
overlap with the larger one). We then estimated effect
sizes (ES) and 95% CIs through both fixed and random
effects models [35]. We also estimated the 95% predic-
tion interval, which further accounts for between-study
heterogeneity, and evaluates the uncertainty of the effect
that would be expected in a new study addressing the
same association [36, 37]. For the largest dataset of each
meta-analysis, we calculated the standard error of the
ES. If the standard error is < 0.1, then the 95% CI will be
< 0.20 (i.e., less than the magnitude of a small ES). We
calculated the I2 metric to quantify between-study het-
erogeneity. Values ≥ 50% indicate large heterogeneity,
and values ≥ 75% are indicative of very large heterogen-
eity [38, 39]. To assess evidence for small-study effects
we used the asymmetry test developed by Egger et al.
[40]. A P value < 0.10 in the Egger’s test and the ES of
the largest study being more conservative than the sum-
mary random effects ES of the meta-analysis were con-
sidered indicative of small-study effects [41]. Finally,
evidence of an excess of significance was assessed by the
Ioannidis test [42]. Briefly, this test estimates whether
the number of studies with nominally significant results
(i.e., P < 0.05) among those included in a meta-analysis is
too large considering their power to detect significant ef-
fects at an alpha level of 0.05. First, the power of each
study is estimated with a non-central t distribution. The
sum of all power estimates provides the expected (E)
number of datasets with nominal statistical significance.
The actual observed (O) number of statistically signifi-
cant datasets is then compared to the E number using a
χ2-based test [42]. Since the true ES of a meta-analysis
cannot be precisely determined, we considered the ES of
the largest dataset as the plausible true ES. This decision
was based on the fact that simulations indicate that the
most appropriate assumption is the ES of the largest
dataset included in the meta-analysis [43]. Excess signifi-
cance for a single meta-analysis was considered if P <
0.10 in Ioannidis’s test and O > E. We graded the cred-
ibility of each association with standard approaches on
the following categories [31, 44]: convincing (class I),
highly suggestive (class II), suggestive (class III), weak
evidence, and non-significant associations (Table 1).
For associations supported by either class I or II evi-
dence, we conducted additional analyses. First, grading of
the evidence was re-assessed through sensitivity analyses
(when at least three independent datasets were available
for each subgroup). The following analyses were consid-
ered: (1) prospective cohort studies; (2) studies in which
the ascertainment of depression was performed by means
of a structured diagnostic interview; (3) studies that pro-
vided estimates adjusted for potential confounding vari-
ables through multivariable models; (5) studies from
which estimates were adjusted at least for sex and age; (6)
studies that adjusted for characteristics of the underlying
somatic disease (i.e., whenever the association of depres-
sion and mortality was assessed in a population with a
specific somatic condition); (7) studies that adjusted esti-
mates for the presence of co-morbid diseases (including
mental and/or somatic conditions); (8) settings where
samples were derived from (community, primary care,
outpatient samples, or inpatient samples); and (9) studies
in which the follow-up time was longer than 5 years. Fi-
nally, we used credibility ceilings, which is a method of
sensitivity analyses to account for potential methodo-
logical limitations of observational studies that might lead
to spurious precision of combined effect estimates. In
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brief, this method assumes that every observational study
has a probability c (credibility ceiling) that the true effect
size is in a different direction from the one suggested by
the point estimate [45, 46]. The pooled effect sizes were
re-estimated considering a wide range of credibility ceiling
values [30, 45]. All analyses were conducted in STATA/
MP 14.0 (StataCorp, USA) with the metan package.
Two investigators (MOM and NV) independently
rated the methodological quality of included systematic
reviews and meta-analyses with the Assessment of Mul-
tiple Systematic Reviews (AMSTAR) instrument, which
has been validated for this purpose [47–49]. Scores
range from 0 to 11 with higher scores indicating greater
quality. The AMSTAR tool involves dichotomous scor-
ing (i.e., 0 or 1) of 11 related items to assess methodo-
logical rigor of systematic reviews and meta-analyses
(e.g., comprehensive search strategy, publication bias as-
sessment). AMSTAR scores are graded as high (8–11),
medium (4–7), and low quality (0–3) [47].
Results
Overall, the title and abstract of 4983 references were
screened for eligibility. The full-text of 52 references
were then scrutinized in detail, of which 19 were ex-
cluded with reasons (Additional file 1: Table S1), while
26 references met inclusion criteria (Fig. 1). Overall, 24
references provided quantitative synthesis of evidence
[16, 19, 20, 26–28, 50–67], and 2 references were quali-
tative systematic reviews [68, 69]. This umbrella review
included 238 prospective studies and 8 retrospective co-
hort studies and comprised data from 3,825,380
participants, including 293,073 participants with depres-
sion and 282,732 death events, which were grouped in
17 meta-analytic estimates (Additional file 1: Table S2).
Overall, 246 eligible studies were derived from included
meta-analyses, while 667 component studies were ex-
cluded from eligible meta-analyses due to the following
reasons: datasets were included in more than one
meta-analysis (k = 375); other mental disorders (e.g., dys-
thymia) were considered in the association between de-
pression and mortality (k = 14); a diagnosis of depression
was based only on clinical evaluation without any speci-
fication of the diagnostic criteria (k = 7); a diagnosis of
depression was based only on the use of antidepressants
(k = 5); the association included other outcomes besides
mortality (e.g., recurrence) (k = 5); overlapping samples
(k = 20); did not provide data for ES estimation (k = 12);
a diagnosis of depression was not established according
to inclusion criteria (k = 223); and assessed the impact of
depression on mortality considering standardized mor-
tality ratios against general population data external to
the study (k = 6). Overall, 165 studies (67.1%) provided
adjusted association metrics, with a median number of 5
(IQR 3–8) covariates controlled for in multivariable
models (see Additional file 1: Table S3 for the list of fac-
tors that were considered in multivariable models in
studies derived from eligible meta-analyses). The median
follow-up time of included studies was 4.5 years (IQR 2–
7.5). The median AMSTAR score of eligible systematic
reviews and meta-analyses was 6 (IQR 5–7.5). Scores of
each domain of the AMSTAR instrument are provided
in Additional file 1: Table S4.
Evidence from qualitative systematic reviews
A systematic review that included 3 studies suggested
that depression could be associated with reduced
long-term survival in patients with head and neck can-
cers [68]. In addition, a systematic review that included
11 studies that assessed the association of depression
and mortality in chronic pulmonary obstructive pul-
monary disease (COPD) met inclusion criteria. The au-
thors concluded that depression could be associated
with an increase in early mortality in patients with
COPD [69].
Summary effect sizes
At a threshold of P < 0.05, summary ESs were significant
for all 17 (100%) meta-analytic estimates in both fixed
and random effects models (Additional file 1: Table S2).
At a more conservative threshold of P < 0.001, 16
(94.1%) and 9 (52.9%) estimates were significant in fixed
and random effects models, respectively. At a threshold
of P < 10− 6, 12 (70.6%) and 5 (29.4%) meta-analyses were
statistically significant in fixed and random effects
models, respectively.
Table 1 Criteria for classification of the credibility of the
evidence (adapted from reference [31])
Classification Criteria
Convincing evidence
(Class I)
More than 1000 death events
Significant summary associations (P < 10− 6)
per random effects calculations
No evidence of small-study effects
No evidence of excess of significance
Prediction intervals not including the null
Not large heterogeneity (i.e., I2 < 50%)
Highly-suggestive
evidence (Class II)
Significant summary associations (P < 10− 6)
per random effects calculation
More than 1000 death events
The largest study with 95% confidence
intervals excluding the null
Suggestive evidence
(Class III)
More than 1000 death events
Significant summary associations (P < 10−3)
per random effects calculations
Weak evidence All other associations with P < 0.05
Non-significant
associations
All associations with P > 0.05
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Heterogeneity between studies
Six meta-analyses (35.6%) showed large heterogeneity
(I2 = 50–75%) and 5 (29.4%) exhibited very large hetero-
geneity (I2 > 75%) (Additional file 1: Table S5). We fur-
ther assessed the uncertainty of the summary effects by
calculating their 95% prediction intervals; the null value
was excluded in only 3 associations, namely in all-cause
mortality in coronary artery bypass graft patients, coron-
ary heart disease patients, and COPD patients.
Small-study effects
Evidence of small-study effects was verified in 13
meta-analyses, including associations of depression and
all-cause mortality in patients after coronary artery by-
pass grafting, with acute coronary syndrome or coronary
heart disease, after stroke, post-transplant patients, and
people with HIV, chronic kidney disease, heart failure,
COPD, diabetes mellitus, and mixed settings, as well as
associations with depression and fatal stroke and cardio-
vascular mortality after acute myocardial infarction
(Additional file 1: Table S5) [51].
Excess significance
We assessed excess of significance bias (i.e., the likelihood
that the observed number of nominally significant studies
could exceed the expected number of ‘positive’ studies for
a given estimate). Eleven (64.7%) meta-analyses had evi-
dence of excess significance bias, namely those investigat-
ing the associations of all-cause mortality and cancer,
heart failure, mixed settings, coronary heart disease, acute
coronary syndrome, stroke, post-transplant patients,
chronic kidney disease, as well as associations of depres-
sion and fatal stroke, cardiovascular mortality in patients
with diabetes mellitus, and cardiovascular mortality in
mixed settings (Additional file 1: Table S5).
Grading of the evidence
We explored whether the nominally significant associa-
tions between mortality and depression were supported by
convincing, highly suggestive, suggestive, or weak evidence
(Table 2). Overall, no association was supported by con-
vincing evidence, while associations of depression and
all-cause mortality among patients with cancer, patients
after acute myocardial infarction, patients with heart fail-
ure, and mixed settings (including inpatients, outpatients,
and community as well as primary care samples) were
supported by highly suggestive evidence. Furthermore, as-
sociations between depression and all-cause mortality in
patients with coronary heart disease and diabetes mellitus
were supported by suggestive evidence. Finally, the
remaining 11 (64.7%) associations were supported by weak
evidence (Table 2).
Sensitivity analyses
Sensitivity analyses were performed for the four associa-
tions supported by highly suggestive evidence as per our
protocol (Table 3). It is worth noting that, when studies
that employed structured/semi-structured diagnostic
Fig. 1 Study flowchart
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Table 3 Sensitivity analyses for associations of depression and all-cause mortality supported by highly suggestive (class II) evidence
Subgroup Sample size
MDD/Deaths
k Largest study
ES (95% CI)a
Random effects
summary
ESb (95% CI)
Random
effects P
valuec
95%
prediction
interval
I2
(%)
Excess significance Classification
O/Ed P value
All-cause in cancer
Structured interview 145/462 5 2.85 (2.29–3.54) 1.56 (0.87–2.8) 0.133 0.28–8.56 71.9 1/1.02 0.979 Weak
Adjusted estimates only 1066/2273 13 1.2 (0.9–1.4) 1.6 (1.35–1.9) < 10−6 1.02–2.51 42.3 8/5.16 0.097 Class III
Adjusted at least for age and sex 691/1030 6 1.2 (0.9–1.4) 1.69 (1.23–2.31) 0.001 0.77–3.68 51.6 4/3.3 0.563 Class III
Adjusted comorbidities 910/1951 9 1.2 (0.9–1.4) 1.52 (1.27–1.83) < 0.001 0.97–2.4 43.3 5/3.54 0.3 Class III
Inpatients 764/618 10 1.66 (1.16–2.37) 1.7 (1.35–2.13) < 0.001 0.96–3 40.9 6/3.55 0.106 Weak
Outpatients 453/1418 10 1.3 (0.98–1.73) 1.56 (1.11–2.17) 0.009 0.57–4.28 75.3 4/2.57 0.291 Class III
Prospective studies 4034/4817 23 1.37 (1.26–1.5) 1.55 (1.32–1.81) < 10−6 0.86–2.78 69.6 11/6.21 0.023 Class II
Follow-up ≤ 5 years 946/1580 15 1.2 (0.9–1.4) 1.8 (1.42–2.28) < 0.001 0.83–3.9 68.1 9/6.64 0.22 Class III
Follow-up > 5 years 3088/3237 8 1.37 (1.26–1.5) 1.29 (1.14–1.47) < 0.001 1–1.68 22.5 2/1.52 0.658 Class III
All-cause in heart failure patientse
Adjusted estimates only 3383/4275 21 1.33 (1.19–1.42) 1.46 (1.29–1.64) < 10−6 0.93–2.27 79.1 14/9.83 0.068 Class II
Adjusted at least for age and sex 2526/2935 13 1.33 (1.19–1.42) 1.36 (1.22–1.52) < 10−6 0.99–1.86 54.3 9/5.39 0.042 Class II
Adjusted for comorbidities 2395/3371 12 1.33 (1.19–1.42) 1.43 (1.26–1.62) < 10−6 1–2.04 60.5 8/6.58 0.41 Class II
Inpatients 1245/1500 7 2.02 (1.48–2.76) 1.82 (1.28–2.6) < 0.001 0.64–5.19 77.7 4/5.12 0.339 Class III
Outpatients 639/583 6 1.31 (1.07–1.6) 1.46 (1.08–1.96) 0.013 0.67–3.16 75.2 4/1.8 0.049 Weak
Prospective studies 3418/4345 22 1.33 (1.19–1.42) 1.46 (1.3–1.65) < 10−6 0.94–2.28 78.4 14/10.02 0.088 Class II
Follow-up ≤ 5 years 2417/2358 16 1.33 (1.19–1.42) 1.52 (1.3–1.77) < 10−6 0.93–2.47 80.0 10/6.55 0.079 Class II
Follow-up > 5 years 1001/1987 6 1.31 (1.07–1.6) 1.4 (1.14–1.72) 0.001 0.76–2.57 72.5 4/3.41 0.627 Class III
All-cause in mixed samplee
Structured interview 4746/29667 19 2.3 (2.1–2.5) 1.64 (1.3–2.08) < 0.001 0.62–4.38 88.7 11/13.06 0.277 Class III
Adjusted estimates only 83,470/212385 81 1.77 (1.41–2.17) 1.42 (1.33–1.5) < 10−6 0.93–2.15 86.5 44/16.69 0 Class II
Adjusted at least for age and sex 51,332/161660 42 1.1 (1.07–1.13) 1.34 (1.25–1.43) < 10−6 0.96–1.85 82.4 23/15.72 0.017 Class II
Adjusted for comorbidities 34,122/41488 53 1.77 (1.41–2.17) 1.38 (1.29–1.47) < 10−6 0.97–1.96 71.6 31/3.66 0 Class II
Community 32,269/69181 62 1.77 (1.41–2.17) 1.48 (1.36–1.61) < 10−6 0.83–2.63 88.2 31/8.76 0 Class II
Inpatients 2209/2334 16 1.44 (1.1–1.88) 1.58 (1.33–1.87) < 10−6 0.93–2.68 56.0 10/5.69 0.019 Class II
Outpatients 811/497 6 1.55 (1.06–2.26) 1.47 (1.13–1.91) 0.004 0.8–2.68 34.5 4/0.58 0 Weak
Primary care 8730/4558 6 1.04 (0.93–1.15) 1.44 (1.11–1.86) 0.006 0.67–3.1 82.0 4/2.13 0.11 Class III
Prospective studies 46,951/96860 95 1.77 (1.41–2.17) 1.51 (1.4–1.62) < 10−6 0.86–2.63 87.1 51/11.97 0 Class II
Follow-up ≤ 5 years 24,944/26135 61 1.37 (1.19–1.48) 1.62 (1.48–1.77) < 10−6 0.96–2.71 75.7 34/17.79 0 Class II
Follow-up > 5 years 62,689/216442 40 1.77 (1.41–2.17) 1.36 (1.24–1.48) < 10−6 0.81–2.26 93.8 21/8.41 0 Class II
All-cause in post-AMI
Structured interview 1688/638 5 1.48 (1.12–1.96) 2.37 (1.36–4.14) 0.002 0.41–13.76 86.3 4/4.12 0.886 Weak
Adjusted estimates only 2381/1771 9 1.48 (1.12–1.96) 2.2 (1.51–3.2) < 0.001 0.71–6.81 80.7 7/7.88 0.374 Class III
Adjusted for comorbidities 1507/579 3 1.48 (1.12–1.96) 1.56 (1.18–2.06) 0.001 0.79–3.1 5.1 2/2.15 0.843 Weak
Inpatients 3998/2196 17 1.48 (1.12–1.96) 2.09 (1.63–2.69) < 10−6 0.9–4.85 70.3 10/12.89 0.102 Class II
Prospective studies 4183/2358 20 1.48 (1.12–1.96) 2.09 (1.66–2.63) < 10−6 0.95–4.62 66.6 12/14.72 0.168 Class II
Follow-up ≤ 5 years 3602/1789 16 1.67 (1.31–2.12) 2.18 (1.66–2.86) < 10−6 0.89–5.32 69.4 9/12.4 0.042 Class II
Follow-up > 5 years 533/560 3 1.48 (1.12–1.96) 1.57 (1.25–1.99) < 0.001 0.94–2.63 0.0 2/1.31 0.42 Weak
AMI acute myocardial infarction, CI confidence interval, E expected, ES effect size, MDD major depressive disorder, NA not available, NE not evaluated,
NS not significant, O observed
aES and 95% confidence interval of largest study (smallest standard error) in each meta-analysis
bRandom effects refer to summary effect size (95% CI) using the random effects model
cP value of summary random effects estimate
dExpected number of statistically significant studies using the point estimate of the largest study (smallest standard error) as the plausible effect size
eInclude community samples, inpatients, outpatients and primary care
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interviews were considered, associations of depression
and all cause-mortality in cancer as well as post-acute
myocardial infarction became supported by weak evi-
dence, while the association of depression and all-cause
mortality in mixed settings dropped to suggestive
evidence. Furthermore, when only studies that provided
adjusted estimates were considered, associations of
depression and all-cause mortality in cancer and
post-acute myocardial infarction dropped to suggestive
evidence. Moreover, the association of depression and
all-cause mortality in cancer was supported by suggest-
ive evidence only when studies that adjusted at least for
age and sex were assessed in analysis.
Sensitivity analyses through credibility ceilings were also
conducted for the four associations supported by highly
suggestive evidence (Additional file 1: Table S6). All asso-
ciations remained significant when 10% credibility ceilings
were considered, while no associations were nominally
significant when 20% credibility ceilings were considered.
Discussion
The associations between mental disorders and mortality
have been investigated for more than 150 years [70, 71].
The associations between depression and all-cause and
cause-specific mortality has been particularly investigated
across different types of settings and populations. All
meta-analyses have obtained nominally statistically signifi-
cant results for a higher risk of mortality in almost all the
tested populations. However, no associations met criteria
for convincing evidence, while only four associations,
namely those of depression and all-cause mortality in can-
cer, heart failure, mixed settings as well as among patients
after acute myocardial infarction, were supported by
highly suggestive evidence. Nevertheless, our sensitivity
analyses indicate that differences in case ascertainment of
depression as well as the lack of proper adjustment for
confounding variables and other major risk factors could
render several associations supported by lower levels of
evidence. Therefore, the current work suggests that causal
inferences between depression and all-cause mortality
across distinct populations do not appear to be as conclu-
sive as once thought [16, 21, 72].
Several variables and mechanisms may contribute to
the observed associations of depression and all-cause
mortality. Some effects may be direct. For example, it
has been suggested that depression activates several
pathophysiological mechanisms that could contribute to
the emergence of chronic somatic diseases that are con-
sistently related to lowered survival. For instance, it has
been claimed that depression is associated with periph-
eral inflammation [73] and oxidative stress [74], mecha-
nisms which may contribute to the association of
depression and obesity and cardio-metabolic conditions
[66, 75–77]. However, depression may also exert indirect
effects on survival. For example, a large body of evidence
suggests that depression alters illness behavior [78], lead-
ing to a meaningful decrease in treatment adherence
across several conditions [79, 80] as well as unhealthy
lifestyles (e.g., sedentary behavior, higher prevalence of
smoking, and non-salutary diet) [23, 73, 81, 82]. Depres-
sion also often co-exists with other mental health condi-
tions that may also be associated with elevated mortality
rates [25, 72]. Multivariable adjustment has varied across
included studies, and only approximately 40% of in-
cluded studies controlled their results at least for age
and sex. Mortality analyses that do not account for at
least these two major determinants of death risk are
problematic. We observed that, when only studies that
controlled for age and sex were considered, the associ-
ation of depression and all-cause mortality in cancer was
no longer supported by highly suggestive evidence. Fur-
thermore, no association was supported by highly sug-
gestive evidence when only studies that employed
structured/semi-structured diagnostic interviews were
considered. This is a relevant finding since recent evi-
dence suggests that the selective use of different cutoff
points may bias accuracy estimates of screening instru-
ments for depression, even if these instruments are con-
sidered to be validated, whilst this type of bias does not
apparently occur in gold-standard structured diagnostic
interviews [83]. It is worthy to note, however, that the
association between depression and all-cause mortality
among patients with heart failure remained supported
by highly suggestive evidence when only studies that
provided either adjusted estimates or, otherwise, that ad-
justed for age and sex were considered, while due to the
lack of available datasets sensitivity analyses considering
studies that used structured/semi-structured diagnostic
interviews could not be performed. Therefore, further
studies should be conducted to evaluate this association.
Comparison with other studies
Cuijpers et al. [51] performed the largest meta-analysis to
date assessing the impact of depression on mortality. Al-
though this previous meta-analysis concluded that depres-
sion is associated with all-cause mortality, fewer studies
were available when that study was conducted. In addition,
the inclusion criteria differed from ours. For example,
Cuijpers et al. [51] included studies in which a diagnosis of
depression was based on previous exposure to antidepres-
sants, which are drugs used for several other medical and
psychiatric indications, whilst we limited our inclusion cri-
teria to investigations in which depression was assessed by
either a structured/unstructured diagnostic interview or a
screening instrument with a cut-off score, and also
large-scale studies that used a coded diagnosis of depression
based on well-established criteria. In addition, we estimated
the credibility of the evidence in different settings and
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populations with state-of-the art statistical methods used in
previous umbrella reviews [8, 30].
A previous meta-review investigated the associations be-
tween severe mental disorders (including depression) and
all-cause and suicide-related mortality [72]. Although the
authors concluded that depression was associated with an
excess of all-cause mortality, only three references were
included and the credibility of the evidence was not quan-
titatively assessed. Finally, a recent study pooled evidence
from 15 systematic reviews and meta-analyses and ob-
served that evidence that depression is associated with
all-cause mortality remains inconclusive [84]. This previ-
ous effort is the most comprehensive assessment of the
impact of depression on mortality conducted to date. The
inclusion criteria differed from ours. Furthermore, in the
current effort, an attempt to demarcate the putative im-
pact of depression on survival in different populations was
performed. In addition, we assessed several hints of biases
in this literature. Our findings provide further quantitative
evidence that the causality of associations between depres-
sion and elevated all-cause mortality across different pop-
ulations and settings remains to be proven.
Strengths and limitations
Our umbrella review might have missed some available
evidence, e.g., recently published studies that had not
been included in the prior meta-analyses [29]. However,
in this effort, we assessed all available systematic reviews
and meta-analyses, and all unique datasets which met
inclusion criteria were synthesized for each estimate
from all available meta-analyses and most considered
meta-analyses were very recent. Although several hints
of bias were found to be prevalent in this literature, it is
relevant to mention that this finding does not exclude
the presence of genuine (i.e., true) heterogeneity in this
field. Moreover, the Ioannidis test has relatively low
power in a context of high heterogeneity [42], while the
assumption that the largest study could approximate the
underlying ‘true’ effect size of a meta-analysis may be
less straightforward for observational studies than for
randomized controlled trials. Depression is a heteroge-
neous phenotype with different symptomatic dimensions
and subtypes [85]. For example, a model has proposed
that the duration and specific dimensions of depression
(i.e., ‘cognitive/affective’ versus ‘somatic/affective’) may
have a differential impact on the progression of coronary
artery disease after acute coronary syndrome [86]. This
framework was supported by a previous meta-analysis
that has shown that somatic/affective symptoms of de-
pression may exert a stronger deleterious effect upon
mortality compared to cognitive/affective symptoms in
patients with heart disease [87]. In addition, a recent
individual-patient meta-analysis suggested that, follow-
ing proper adjustment for cardiovascular factors, the
association between depression and all-cause mortality is
notably attenuated in patients after an acute myocardial
infarction [67]. This finding underscores that the extent
of proper or suboptimal adjustment of clinical and
sociodemographic variables may render the association
between depression and mortality less consistent across
populations with chronic diseases. Although we con-
ducted several sensitivity analyses, the reporting and
multivariable adjustment to potential confounders was
not consistent across included studies, thus limiting the
quality of available evidence. It is possible that more
studies adjusted their results at least to age and sex but
considered it so trivial that they did not even report on
this. Therefore, more thorough reporting of model speci-
fication and adjustment is needed in future studies.
Finally, depression may manifest in samples with chronic
somatic conditions differently. For example, the diagnosis
of depression in cancer patients has been a matter of de-
bate, and may also be ascribed as a spectrum of syndromes
[88, 89], some of which may not be properly captured by
conventional diagnostic criteria (e.g., DSM-5 or ICD-10)
[88]. Furthermore, there is a spectrum related to the timing
of appearance with symptoms. In some circumstances, de-
pression may either antedate or be considered an initial
manifestation of chronic somatic diseases [78, 90], whilst in
other circumstances depression may occur after the onset
of the medical condition [78], and also as a result of treat-
ment and its complications. The current effort could not
elucidate how the temporal relationship between depres-
sion and the respective chronic medical condition could
potentially influence mortality rates.
Implications
Our findings suggest that available evidence does not
consistently allow the establishment of causal inferences
linking depression to all-cause and cause-specific mor-
tality across different settings and populations. Yet, the
association of depression and all-cause mortality appears
to be complex, and may be influenced by several socio-
demographic and clinical variables. Moreover, we do not
question the association between depression and suicide
where the evidence is unquestionable [18, 91, 92]. How-
ever, suicides appear to account for a relatively smaller
fraction of deaths compared to natural causes of death
among people with depression [93–95].
The current data may also reconcile some controversies
in existing literature. For example, although previous evi-
dence has suggested that post-acute myocardial infarction
depression might be associated with diminished survival,
no conclusive evidence indicated that the treatment of de-
pression translates to an increased survival in this specific
population [96, 97]. Therefore, findings from this umbrella
review of observational studies and data from intervention
studies conducted to date appear to concur in that
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associations between depression and all-cause and
cause-specific mortality are unlikely to be causal.
For other conditions, such as cancer, it remains unclear
if prevention and treatment of depression may increase
overall survival. Management of depression is worthwhile
for various other reasons, e.g., improvement of quality of
life, but not with the expectation that death risk will de-
crease. Furthermore, interventions aiming to promote a
healthy lifestyle as well as the proper care of co-occurring
somatic conditions in those with depression may also lead
to a decrease in all-cause mortality [25]. However, the im-
pact of those interventions at an individual, societal, and
health system levels upon all-cause survival warrant fur-
ther investigation.
Conclusions
The associations between depression and all-cause and spe-
cific natural cause mortality has been extensively investi-
gated in a wide range of populations and settings. However,
this umbrella review of observational studies indicates that
the evidence for causal associations of depression and
all-cause mortality remains inconclusive. To draw firmer
conclusions, further prospective and collaborative studies
with transparent a priori-defined protocols and a proper
multivariable adjustment to confounders and other import-
ant risk determinants for mortality are warranted.
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